MYGN Stock Cash Flow Statements

Myriad Genetics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Myriad Genetics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2003-12-31	2003-09-30	2003-06-30	2003-03-31

cash flows from operating activities:
net income	-330,500,000	-100,000	-42,500,000	-22,100,000	-36,700,000	-26,000,000		-61,300,000	-116,100,000	-54,700,000																					4,200,000	5,900,000	-1,200,000	35,700,000	32,600,000	30,400,000	26,600,000	18,712,000	21,475,000	24,031,000	15,982,000	33,632,000	36,768,000	50,360,000	55,465,000	44,074,000	37,893,000	35,036,000	30,136,000	29,142,000	25,099,000	26,040,000	27,941,000	24,191,000	22,538,000	53,250,000	33,251,000	35,360,000	30,442,000	23,640,000	25,318,000	21,203,000	14,454,000	65,541,000	-4,631,000	-5,066,000	-7,999,000	-7,804,000	-5,937,000	-8,796,000	-12,425,000	-11,424,000	-9,571,000	-7,952,000	-9,242,000	-9,854,000	-9,609,000	-7,081,000	-5,533,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	14,100,000	14,400,000	14,800,000	15,600,000	15,100,000	15,700,000	15,100,000	14,100,000	13,300,000	19,400,000	13,700,000	13,100,000	12,900,000	13,000,000	13,300,000	14,200,000	16,900,000	18,400,000	17,700,000	17,700,000	17,900,000	18,200,000	18,200,000	18,400,000	18,300,000	18,000,000	18,300,000	15,100,000	13,000,000	13,300,000	12,900,000	12,900,000	9,200,000	6,700,000	6,500,000	6,700,000	6,800,000	6,611,000	6,399,000	6,036,000	5,954,000	5,528,000	3,480,000	2,439,000	2,372,000	2,254,000	2,180,000	2,244,000	2,211,000	2,328,000	2,147,000	1,878,000	1,800,000	1,784,000	1,757,000	1,792,000	1,778,000	1,735,000	1,779,000	2,439,000	2,408,000	2,346,000	2,256,000	2,259,000	2,287,000	2,167,000	2,068,000	2,008,000	1,955,000	1,824,000	1,757,000	1,804,000	1,717,000	1,691,000	1,643,000	1,435,000	1,419,000	1,306,000	1,294,000
non-cash lease expense	2,800,000	2,800,000	2,800,000	2,300,000	2,100,000	2,300,000	2,700,000	2,800,000	2,900,000	2,900,000	3,100,000	2,900,000	2,600,000	3,100,000	3,000,000	3,000,000	3,300,000	3,500,000	3,300,000
stock-based compensation expense	10,700,000	9,500,000	10,900,000	12,400,000	14,500,000	12,000,000	10,400,000	11,600,000	11,200,000	7,500,000	8,200,000	9,400,000	10,400,000	10,100,000	8,400,000	10,000,000
deferred income taxes			200,000	-1,400,000	-2,200,000	600,000	-2,300,000	-1,000,000	-800,000	100,000	-8,800,000	-11,400,000	-4,700,000	-5,900,000	-4,300,000	-16,300,000	300,000	-11,800,000	48,400,000		-16,100,000	-1,700,000	-5,100,000	15,600,000	700,000	-400,000	2,700,000	1,400,000	1,000,000	-700,000	-900,000	-300,000	3,200,000	-13,400,000	1,700,000	18,400,000	11,400,000	643,000	-2,934,000	-798,000	2,689,000	6,297,000	3,653,000	-1,238,000	-588,000	2,449,000	-879,000	3,675,000	2,224,000	-574,000	14,786,000	13,565,000	13,708,000	13,345,000	12,538,000
unrecognized tax benefits	-200,000	-31,300,000	1,300,000	300,000	300,000	600,000	600,000	500,000	400,000	1,900,000	-1,200,000	300,000	-400,000	200,000	-4,100,000	1,100,000	100,000	300,000	13,900,000	1,100,000	-100,000	300,000	400,000		-5,000,000	300,000	-2,600,000	-3,000,000	-5,500,000	300,000	300,000	200,000	400,000	0	-3,900,000	600,000	900,000	227,000	785,000	812,000	276,000	-3,583,000	323,000	962,000	1,638,000	240,000	340,000	0	130,000	0		200,000	648,000	-529,000	-467,000
impairment of goodwill and long-lived assets			43,000,000	800,000	11,600,000	1,200,000					6,200,000	0	0	10,700,000	0	0
gain on termination of lease				0	0	-3,100,000
gain on acquisition			0	0	0	-2,200,000
other non-cash adjustments	-200,000	500,000	-500,000	200,000	900,000	900,000	-100,000	1,300,000
changes in assets and liabilities:
prepaid expenses and other current assets	2,500,000	-2,200,000	900,000	-2,500,000	3,100,000	-5,200,000	2,000,000			-4,000,000	1,200,000	-1,900,000	5,300,000	-3,000,000	100,000
trade accounts receivable	-16,200,000	800,000	4,000,000	-8,200,000	-600,000	-3,900,000	1,200,000	-3,600,000	7,400,000	-17,500,000	2,500,000	6,100,000	-8,400,000	-10,500,000	2,800,000	700,000	-7,600,000	-4,700,000	-17,000,000	34,500,000	15,900,000	-3,100,000	16,700,000		-26,100,000	2,400,000	-3,300,000	3,100,000	-9,800,000	-1,100,000	-15,900,000	-18,500,000	-5,900,000	-10,500,000	-17,600,000	-7,500,000	-3,600,000	-2,161,000	-18,353,000	-12,365,000	-1,521,000	-7,065,000	-5,710,000	-8,218,000	-3,379,000	-11,351,000	-25,983,000	-20,591,000	-9,260,000	-16,758,000	1,181,000	-4,017,000	-10,161,000	-423,000	-388,000	-4,422,000	-3,836,000	-9,862,000	-3,540,000	-951,000	-10,187,000	1,540,000	-10,303,000	-4,112,000	-3,960,000	-8,462,000	-4,526,000	-7,452,000	-2,981,000	-2,458,000	-3,042,000	-795,000	-2,291,000	-564,000	-2,048,000
inventory	-300,000	-900,000	-1,300,000	0	-3,100,000	-1,800,000	3,200,000	-2,700,000	-600,000	-1,700,000	1,500,000	-4,300,000	100,000	-200,000	3,200,000	-800,000	-3,200,000	2,400,000	2,600,000			-500,000	3,100,000	600,000	1,300,000	2,600,000	3,500,000	-1,000,000	4,800,000	5,300,000	3,900,000	2,600,000	-13,000,000	-14,400,000	3,900,000	5,100,000	-9,200,000	4,121,000	-8,667,000	4,602,000	-856,000	-5,399,000				2,129,000	3,331,000	135,000	972,000	-1,246,000	-1,488,000
prepaid taxes	0	2,100,000	600,000	1,300,000	0	-1,400,000	500,000	300,000			200,000	1,400,000	-500,000	-400,000	-18,100,000	18,200,000	-500,000	90,300,000	-107,900,000	25,400,000	-700,000	-1,700,000	2,100,000		100,000	500,000	-3,600,000		4,700,000	0	4,000,000	600,000	-1,000,000	11,500,000	12,700,000	-14,500,000	-13,500,000	-9,000	5,602,000	13,096,000	-5,089,000	-521,000
other assets	200,000	500,000		-900,000	500,000	200,000	800,000	4,900,000	-2,800,000	-2,300,000	-400,000	500,000	-700,000	-300,000	-400,000	-900,000	-1,500,000	-1,200,000	-1,200,000
accounts payable			-1,100,000	-3,600,000	3,300,000	6,100,000	-5,900,000	-8,500,000	3,100,000	7,600,000	-2,400,000	7,100,000	-5,000,000	-3,200,000	14,000,000	-12,900,000	7,800,000	300,000	-3,200,000		9,200,000	-2,000,000	-9,300,000	9,200,000	-7,800,000	8,100,000	-8,400,000	6,000,000	-5,000,000	-5,000,000	4,000,000	3,000,000	-5,000,000		-2,800,000	1,200,000	-5,300,000	3,300,000	-155,000	-8,895,000	2,650,000	4,143,000	-5,099,000	-1,149,000	613,000	5,894,000	-1,337,000	2,489,000	945,000	2,207,000	-1,576,000	3,966,000	-1,859,000	-192,000	-1,628,000	1,844,000	-2,377,000	1,755,000	-6,529,000	2,751,000	-1,345,000	-2,228,000	-9,885,000	12,875,000	-1,901,000	-83,000	-1,770,000	4,765,000	-4,199,000	3,547,000	-154,000	1,312,000	-4,216,000	4,988,000	-2,177,000	-1,919,000	-5,645,000
accrued liabilities	-16,800,000	-12,400,000	-27,500,000	6,600,000	-5,400,000	-14,700,000							-47,600,000	-35,300,000	-12,500,000	62,100,000	8,300,000	7,800,000	-9,800,000	17,000,000	-3,600,000	-10,100,000	-1,700,000	100,000	6,100,000	-300,000	-4,400,000	4,000,000	3,200,000	1,300,000	4,400,000	4,500,000	-9,500,000	-2,400,000	3,400,000	5,200,000	-5,700,000	-1,876,000	3,709,000	526,000	-15,759,000	5,310,000	-3,743,000	-13,546,000	15,056,000	5,982,000	9,160,000	-13,804,000	10,224,000	5,068,000	-1,473,000	343,000	2,043,000	977,000	-2,439,000	2,408,000	1,883,000	-37,000	-4,647,000	-2,775,000	-15,801,000	1,643,000	-7,593,000	23,176,000	-526,000	3,027,000	2,062,000	4,003,000	714,000	-398,000	-3,662,000	3,993,000	2,416,000	-1,045,000	-1,508,000	2,753,000	-899,000	583,000	205,000
net cash from operating activities	-13,600,000	-16,300,000	6,600,000	700,000	2,600,000	-18,600,000	-54,700,000	-22,100,000	-900,000	-33,200,000	-7,700,000	-1,800,000	-50,300,000	-46,500,000	-9,900,000	-39,300,000	-4,400,000	71,800,000	-59,300,000	30,000,000	16,800,000	-1,900,000	15,800,000	31,500,000	6,600,000	37,800,000	7,800,000	47,900,000	11,500,000	36,600,000	41,100,000	31,400,000	-2,900,000	56,400,000	44,100,000	40,900,000	24,900,000	51,044,000	29,878,000	52,597,000	6,981,000	40,933,000	11,249,000	47,549,000	90,482,000	63,000,000	37,396,000	22,114,000	51,356,000	41,740,000	31,855,000	36,302,000	28,036,000	37,125,000	29,296,000	46,522,000	42,656,000	42,727,000	23,181,000	38,929,000	7,869,000	41,643,000	-4,399,000	111,840,000	4,444,000	150,000	-12,698,000	254,000	-4,921,000	-6,883,000	-14,301,000	-3,288,000	-6,889,000	-6,900,000	-10,950,000	-6,724,000	-13,675,000
cash flows from investing activities:
capital expenditures	-2,800,000	-5,300,000	-3,600,000	-3,500,000	-5,200,000	-6,700,000	-10,000,000	-10,900,000	-18,800,000	-23,500,000	-14,600,000	-17,700,000	-6,700,000	-6,300,000	-3,400,000	-3,000,000	-4,500,000	-7,100,000	-1,500,000		-3,000,000	-3,400,000	-1,400,000		-3,100,000	-2,800,000	-1,300,000	-1,800,000	-2,900,000	-700,000	-1,500,000	-2,400,000	-1,500,000	-2,200,000	-700,000	-1,100,000	-1,000,000																																-1,393,000	-4,785,000	-2,480,000	-1,834,000	-2,594,000	-2,338,000	-914,000	-1,086,000	-1,443,000
free cash flows	-16,400,000	-21,600,000	3,000,000	-2,800,000	-2,600,000	-25,300,000	-64,700,000	-33,000,000	-19,700,000	-56,700,000	-22,300,000	-19,500,000	-57,000,000	-52,800,000	-13,300,000	-42,300,000	-8,900,000	64,700,000	-60,800,000		13,800,000	-5,300,000	14,400,000		3,500,000	35,000,000	6,500,000	46,100,000	8,600,000	35,900,000	39,600,000	29,000,000	-4,400,000	54,200,000	43,400,000	39,800,000	23,900,000																																-6,314,000	-11,668,000	-16,781,000	-5,122,000	-9,483,000	-9,238,000	-11,864,000	-7,810,000	-15,118,000
capitalization of intangible assets	-4,100,000	-3,000,000
proceeds from maturities and sales of marketable investment securities			0	5,000,000	2,500,000	1,500,000	1,500,000	15,000,000	30,600,000	58,100,000	40,600,000	42,400,000	28,100,000	17,100,000	24,300,000	11,800,000	9,700,000	15,300,000	18,600,000	12,700,000	20,800,000	18,100,000	17,400,000	27,400,000	19,700,000	15,800,000	16,300,000	12,200,000	20,300,000	17,900,000	34,000,000	20,200,000	88,700,000	28,500,000	15,300,000	39,500,000	31,800,000	24,798,000	60,300,000	12,881,000	67,621,000		227,405,000	56,074,000	57,350,000		92,165,000	82,871,000	124,359,000		66,658,000		153,026,000
net cash from investing activities	-6,900,000	-8,300,000	-5,900,000	7,500,000	-6,400,000	-7,100,000	-12,000,000	-2,500,000	11,800,000	34,600,000	-35,600,000	11,400,000	-12,000,000	-41,300,000	-25,900,000	291,000,000	1,100,000	8,200,000	17,100,000	10,300,000	23,300,000	-7,200,000	-7,100,000		-3,800,000	-8,100,000	-279,000,000	8,900,000	-700,000	4,300,000	9,500,000	-2,100,000	-158,000,000	-43,800,000	-16,100,000	-40,500,000	9,000,000		24,885,000	-8,748,000	27,576,000	-19,861,000	-471,000	10,722,000	-8,057,000	-84,629,000	48,081,000			-8,174,000	-2,532,000	-60,938,000	42,480,000	-52,605,000	16,673,000	11,971,000	-13,429,000	-76,522,000	1,312,000	-45,964,000	-17,851,000	-101,161,000	-41,366,000	-19,982,000	20,017,000	-1,325,000	-30,015,000	-58,411,000	6,922,000	1,202,000	3,546,000	-8,086,000	-9,090,000	-54,698,000	-955,000	513,000	265,000	-17,950,000	1,116,000
cash flows from financing activities:
proceeds from common stock issued under stock-based compensation plans			2,900,000	0							2,400,000	900,000	2,700,000	300,000	1,800,000	39,900,000
payment of tax withheld for common stock issued under stock-based compensation plans	0	-5,800,000	-1,200,000	-3,000,000	-500,000	-8,700,000	-1,500,000	-2,200,000	-200,000	-4,900,000	-1,500,000	-3,800,000	-200,000	-5,100,000	-2,900,000	-8,000,000
proceeds from revolving credit facility	0	40,000,000	20,000,000	20,000,000	20,000,000	60,000,000	40,000,000	0
repayment of revolving credit facility	0	-20,500,000	-19,500,000	-20,000,000	-20,000,000	-60,000,000									0	-106,400,000	-50,000,000	-70,000,000			0	0	-8,600,000		-10,000,000	-35,000,000	-40,000,000	-60,000,000	-27,000,000	-68,000,000
payment on finance leases	-100,000	-100,000	-100,000	-100,000	-100,000	-100,000	-100,000
net cash from financing activities	2,600,000	13,600,000	2,100,000	-3,100,000	2,400,000	-8,800,000	121,900,000	-2,500,000	38,400,000	-4,900,000	-2,100,000	-3,600,000	2,500,000	-4,800,000	-1,100,000	-74,500,000	-26,500,000	-48,500,000	-3,900,000		200,000	1,100,000	-12,300,000	-27,800,000	-9,400,000	-32,600,000	252,100,000	-41,300,000	-4,300,000	-63,300,000	-36,700,000	-4,000,000	175,800,000	-64,200,000	-42,200,000	48,400,000	-10,300,000	-40,188,000	-55,984,000	-52,274,000	-28,854,000	-42,049,000	3,421,000	-71,659,000	-101,511,000	13,379,000	-41,577,000	-15,237,000	-37,120,000	-52,029,000	-19,297,000	9,868,000	-70,807,000	-40,156,000	-15,504,000	-67,802,000	12,491,000	3,030,000	3,193,000	-130,140,000	31,682,000	8,270,000	38,264,000	3,484,000	3,356,000	8,534,000	6,497,000	6,718,000	107,002,000	2,924,000	807,000	3,540,000	3,804,000	141,452,000	1,124,000	442,000	40,000	565,000	14,000
effect of foreign exchange rates on cash, cash equivalents, and restricted cash	600,000	100,000	-700,000	1,200,000	-700,000	-800,000	700,000	-600,000	300,000	200,000
change in cash and cash equivalents classified as held for sale
net decrease in cash, cash equivalents, and restricted cash	-17,300,000	-10,900,000				-35,300,000				-3,300,000
cash, cash equivalents, and restricted cash at beginning of the period	0	111,900,000	0	0	0	140,900,000	0	0	0	66,400,000
cash, cash equivalents, and restricted cash at end of the period	-17,300,000	101,000,000	2,100,000	8,600,000	-4,400,000	105,600,000	55,900,000	-27,700,000	49,600,000	63,100,000
(gain) loss on termination of lease
tenant improvement allowance received							0	0	3,100,000	13,200,000	9,400,000
capitalization of internal-use software costs			-2,300,000	-2,800,000	-3,700,000	-1,900,000	-3,500,000
proceeds from the sale of business, net cash sold			0
acquisitions, net of cash acquired																									0	1,100,000	-279,600,000			0	0	-3,100,000	-213,000,000					15,000
purchases of marketable investment securities											-4,400,000	-13,300,000	-33,400,000	-52,100,000	-46,800,000	-64,400,000					-15,800,000	-21,900,000	-23,100,000		-20,400,000	-22,200,000	-14,400,000	-1,500,000	-18,100,000	-12,900,000	-25,600,000	-16,800,000	-32,200,000	-33,100,000	-30,700,000	-78,900,000	-21,800,000	-25,631,000	-32,446,000	-16,754,000	-5,869,000	-56,313,000	-2,790,000	-42,519,000	-60,142,000	-162,003,000	-42,510,000	-112,361,000	-126,903,000	-97,213,000	-41,282,000	-86,190,000	-110,388,000	-181,056,000	-47,519,000	-146,517,000	-110,832,000	-165,041,000	-55,168,000	-91,899,000	-30,762,000	-122,849,000	-63,056,000	-33,421,000	-31,707,000	-45,747,000	-80,826,000	-107,143,000	-47,860,000	-14,553,000	-28,285,000	-49,765,000	-40,035,000	-69,360,000	-6,359,000	-14,827,000	-14,161,000
payment of contingent consideration recognized at acquisition															0	0	0	-3,300,000	-100,000		0	-600,000	-3,300,000
proceeds from underwritten public offering, net of costs and discounts
fees associated with issuance and refinancing of revolving credit facility
net increase in cash, cash equivalents, and restricted cash			2,100,000	8,600,000			55,900,000	-27,700,000
bad debt expense				-100,000																								9,100,000	7,200,000	10,000,000	9,200,000	10,900,000	7,200,000	9,800,000	9,000,000	8,500,000	6,000,000	7,980,000	9,561,000	6,858,000	7,101,000	8,267,000	9,175,000	10,299,000	11,494,000	10,191,000	8,374,000	7,534,000	7,195,000	7,251,000	4,258,000	3,845,000	3,788,000	4,189,000	4,360,000	4,739,000	4,487,000	4,829,000	4,421,000	3,807,000	4,146,000	3,962,000	4,032,000	3,153,000	2,724,000	3,482,000	2,141,000	1,810,000	1,526,000	1,614,000	700,000	489,000	756,000	332,000	537,000	210,000	148,000	100,000	120,000
net realized losses on marketable investment securities							0	100,000	900,000	500,000
deferred revenues						100,000		100,000	0	100,000		0	-400,000	-4,500,000
net income attributable to myriad genetics, inc. stockholders											-42,300,000	-35,100,000	-14,100,000	-20,500,000	-7,600,000	24,600,000	-4,700,000	-39,500,000	-15,200,000		-115,200,000	-8,300,000	-20,600,000	-4,200,000	6,900,000	2,600,000	-700,000	6,500,000	11,400,000
loss on termination of lease
loss on inventory															0	-100,000
gain on sale of businesses and assets															0
deferred revenue																	-7,600,000	-1,600,000	-600,000	28,900,000	200,000				-100,000	-100,000	-200,000	0	-800,000	-100,000	500,000	1,500,000	-1,000,000				-100,000	158,000	-492,000	481,000	253,000	-1,078,000	-1,986,000	3,057,000	-1,148,000	-988,000	310,000	-554,000	1,221,000	685,000	-245,000									-25,000	-172,000	222,000	-2,025,000	-25,000	1,725,000	324,000	-374,000	-24,000	-27,000	376,000	-59,000	-76,000	-190,000	-2,707,000	2,747,000	-154,000	-583,000
proceeds from sale of business and assets
accrued expenses and other liabilities								21,100,000	71,800,000	-6,500,000
fees associated with issuance of revolving credit facility								-200,000
fees associated with refinancing of revolving credit facility											0				0	0	0	-1,200,000
non-cash interest expense										300,000	600,000	700,000	200,000	200,000	200,000	500,000	300,000	500,000	200,000	200,000	100,000	100,000	100,000	100,000	1,500,000	100,000	-1,300,000	100,000	0	0	100,000	200,000	100,000
non-cash impact of foreign currency transactions
gain on sale of assets
proceeds from sale of assets
effect of foreign exchange rates on cash and cash equivalents												-500,000	-200,000	-600,000	100,000	-400,000	-700,000	400,000	700,000	1,400,000	-2,000,000	800,000	300,000	100,000	900,000	200,000	1,500,000	-2,000,000	2,200,000	1,000,000	1,900,000	-4,200,000	3,500,000	-400,000	0	-1,500,000	-300,000	869,000	-3,279,000	-1,669,000	-721,000									-37,000	-31,000
net increase in cash and cash equivalents												5,500,000	-60,000,000	-93,200,000	-36,800,000	176,800,000	-30,500,000	31,900,000		42,700,000								13,500,000	8,700,000	-21,400,000	15,800,000	21,100,000	18,400,000	-52,000,000	-14,200,000	47,300,000	23,300,000				4,982,000	-20,977,000				-8,250,000	43,900,000	-27,160,000	9,231,000	-18,500,000	9,995,000	-14,697,000			30,465,000	-9,309,000			27,686,000									-51,439,000	109,003,000			-7,834,000						-18,818,000	-16,606,000
cash and cash equivalents at beginning of the period												0	0	258,400,000	0	0	0	117,000,000	163,700,000		0	0	93,200,000		0	0	110,900,000		0		0	0	68,500,000		0	0	64,100,000
cash and cash equivalents at end of the period												5,500,000	-60,000,000	165,200,000	-36,800,000	176,800,000	-30,500,000	148,900,000	118,300,000		39,800,000	-8,700,000	89,900,000		-5,700,000	-2,700,000	93,300,000		8,700,000		15,800,000	21,100,000	86,900,000		-14,200,000	47,300,000	87,400,000
payment of contingent consideration																												-1,900,000
repurchase and retirement of common stock																									0					0	0	-10,300,000	-21,300,000	-54,700,000	-45,000,000	-24,900,000	-38,000,000	-44,754,000	-61,994,000	-58,323,000	-45,629,000	-65,689,000	-41,890,000	-77,808,000	-102,316,000	-21,563,000	-44,822,000	-33,684,000	-46,199,000	-60,996,000	-37,181,000	-21,883,000	-88,071,000	-61,930,000	-28,606,000
change in fair value of contingent consideration																400,000	400,000	900,000	-1,100,000	0	2,100,000	0	700,000		0	-1,000,000	-400,000	400,000	-1,100,000	-2,800,000	5,200,000
proceeds from sale of businesses and assets
gain on deconsolidation of subsidiary
prepaid expenses																	-2,600,000	-2,100,000	1,200,000	-1,300,000	3,700,000	-2,800,000	2,600,000		1,200,000	-1,000,000	1,800,000	600,000	-200,000	-3,100,000	2,600,000	500,000	7,800,000	1,500,000	-11,500,000	-4,200,000	7,000,000	-2,555,000	-2,172,000	1,725,000	-2,498,000	-4,649,000	-2,644,000	701,000	1,106,000	579,000	784,000	197,000	-803,000	423,000	-368,000	-2,231,000	1,355,000	1,410,000	-946,000	-1,145,000	3,022,000	1,980,000	-3,918,000	-1,422,000	-62,000	353,000	41,000	3,889,000	3,724,000	1,005,000	-5,789,000	289,000	1,144,000	-2,151,000	545,000	771,000	3,640,000	-2,098,000	-1,308,000	-893,000	101,000
other receivables																	700,000	-400,000	900,000	-300,000	1,200,000	-200,000	-100,000		1,500,000	-1,600,000	-300,000	-3,000,000	2,700,000	-800,000	-800,000	-600,000	-1,800,000	100,000	4,300,000	-5,500,000	200,000	1,545,000	2,516,000	5,913,000	-7,474,000	-1,283,000	-415,000	-1,730,000	1,558,000	-1,179,000	-1,199,000	982,000	690,000	-1,160,000	-79,000	749,000	-948,000	51,000	-54,000		-807,000	636,000	-420,000	3,517,000	-3,459,000	6,432,000	-2,409,000	-2,751,000	582,000	-41,000	-1,211,000	782,000	790,000	-2,174,000	651,000	-323,000	-60,000	-36,000	167,000	3,129,000	1,013,000
proceeds from sale of subsidiary																				0
gain on disposition of assets																		-300,000	100,000				-100,000		0	100,000	-1,000,000	-300,000	0	-100,000	0	0	-200,000	-500,000	0	0	-400,000		95,000												-4,000													0				-648,000
share-based compensation expense																		9,000,000	8,400,000	1,900,000	7,500,000	7,000,000	8,800,000	8,800,000	9,500,000	7,500,000	7,700,000	7,100,000	6,700,000	7,200,000	7,500,000	7,400,000	7,800,000	7,700,000	7,600,000	7,600,000	8,700,000	14,128,000	12,544,000	12,148,000	6,880,000	6,565,000	6,711,000	6,857,000	6,935,000	6,177,000	6,731,000	7,104,000	6,600,000	6,416,000	6,664,000	6,373,000	6,224,000	6,118,000	6,373,000	5,803,000	4,977,000	6,618,000	5,378,000	7,494,000	6,971,000	6,170,000	5,047,000	4,835,000	4,355,000	3,799,000	2,426,000	2,525,000	2,126,000	1,733,000	1,361,000	973,000	887,000	490,000	239,000
impairment of goodwill and intangible assets																				0
cash flows from investing activities
proceeds from common stock issued under share-based compensation plans																		26,500,000
payment of tax withheld for common stock issued under share-based compensation plans																		-500,000
payment for tax withholding for common stock issued under share-based compensation plans																			-3,800,000
net decrease in cash and cash equivalents																			-45,400,000			-8,700,000	-3,300,000		-5,700,000	-2,700,000	-17,600,000												-4,500,000																						21,700,000	-51,248,000	-7,501,000		27,817,000	7,359,000	-36,216,000				-9,948,000				-10,781,000	-5,769,000	-13,370,000
net proceeds from common stock issued under share-based compensation plans																				2,000,000	200,000	1,700,000	-400,000	2,200,000	2,000,000	2,400,000	2,100,000	18,700,000	11,900,000					8,400,000	1,000,000	62,100,000	22,800,000	4,365,000	5,440,000	5,096,000	15,099,000	17,606,000	40,794,000	5,571,000	791,000	32,319,000	1,603,000	15,287,000	8,616,000			17,102,000	775,000	6,439,000	744,000	3,591,000	12,491,000	3,030,000	3,193,000	5,993,000			38,264,000	2,284,000	3,356,000	8,534,000	6,497,000	6,720,000	1,720,000	2,924,000	807,000	3,541,000	3,811,000
proceeds from non-controlling interest																												0	200,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
net proceeds from revolving credit facility																									0	50,000,000	290,000,000	0		0	0
loss on disposition of assets																																									69,000	803,000	12,000	0	40,000	4,000										129,000	302,000	-223,000	288,000							-2,000	274,000			0	27,000	-12,000	23,000
impairment of goodwill classified as held for sale
impairment of cost basis investment																														0	-100,000
loss on extinguishment of debt																														0	0
sale of cost basis investment																														0
net proceeds from term loan																														0	0
repayment of term loan																														0	0
fees associated with restructure of debt
payment of contingent consideration recorded in purchase accounting
fees paid for extinguishment of debt																														0	0
net proceeds from (payments for) common stock issued under share-based compensation plans
net proceeds from issuance of debt																																	199,000,000
excess tax benefit from share-based compensation																																			-1,800,000	-11,200,000	-4,900,000	-201,000	-570,000	-953,000	-1,676,000	-6,034,000	-4,517,000	-578,000	-14,000	-2,623,000	-1,642,000	-3,160,000	-463,000	-1,996,000	-17,040,000	-14,649,000	-16,489,000
net proceeds for common stock issued under share-based compensation plans																															300,000
net proceeds (payments) for common stock issued under share-based compensation plans																																	-1,900,000
accreted interest on note receivable																																										0	-2,004,000	-667,000	-666,000	-667,000	-667,000	-666,000	-667,000	-667,000
gain on remeasurement of foreign currency
restricted cash																																								1,071,000	-22,674,000
impairment of intangible assets
gain on sale of marketable investment securities
equity investment
net cash from (used) in investing activities
changes in operating assets and liabilities:
capital expenditures for equipment and leasehold improvements																																							-4,457,000	-5,946,000	-11,502,000	-4,618,000	-1,555,000	-2,833,000	-5,265,000	-2,791,000	-1,574,000	-4,547,000	-2,461,000	-2,192,000	-2,109,000	-610,000	-158,000	-1,065,000	-1,959,000	-827,000	-1,148,000	-4,343,000	-1,577,000	-2,175,000	-1,841,000	-2,575,000	-934,000	-4,006,000	-1,513,000	-4,874,000	-3,282,000
cash and cash equivalents at beginning of period																																							0	0	64,821,000		0	0	104,073,000		0	0	86,352,000		52,681,000		0	0	92,840,000		0	0	63,510,000		0	0	237,734,000		0	0	143,432,000		0	0	98,573,000		0	0	49,509,000	0	61,603,000		0
cash and cash equivalents at end of period																																							-4,500,000	-10,094,000	69,803,000		14,199,000	-13,388,000	84,987,000		43,900,000	-27,160,000	95,583,000		62,676,000		-291,000	-55,636,000	123,305,000		41,718,000	-30,765,000	91,196,000		21,700,000	-51,248,000	230,233,000		27,817,000	7,359,000	107,216,000		109,003,000	-2,757,000	88,625,000		-12,175,000	79,854,000	38,728,000	-5,769,000	48,233,000		-16,606,000
non-cash expense related to in-process research and development technology																																																		0		500,000	0
acquisition of crescendo biosciences, inc. (see note 12), net of cash acquired
acquisition of rules-based medicine, inc., net of cash acquired
purchase of in-process research and development technology																																																		0		-500,000	0
purchase of other assets																																																		0		0	0			0	0				0	-100,000	-2,000,000
purchase of an acquisition option
issuance of note receivable																																																		0	-17,000,000
proceeds from maturities and sales marketable investment securities
supplemental cash flow information:
cash paid during the year for income taxes
non-cash investing and financing activities:
fair value adjustment on marketable investment securities recorded to stockholders’ equity
impairment of intangible asset																																															0
acquisition of crescendo biosciences, inc. (see note 9), net of cash acquired
net (decrease)/increase in cash and cash equivalents																																													-19,086,000
acquisition of rules-based medicine, inc. (see note 12), net of cash acquired
acquisition of myriad rbm, inc.
crescendo purchase option																																																			-8,000,000
loss of disposition on assets
gain of disposition on assets																																																	1,000
net cash from provided by investing activities																																																	-5,005,000
acquisition of rules-based medicine, inc. (see note 13), net of cash acquired
proceeds from sale of intellectual property
net proceeds from common stock issued undershare-based compensation plans																																																			844,000
(gain) loss on sale of marketable investment securities																																																			-7,000	-38,000	-14,000	39,000	10,000	-236,000	-24,000
acquisition of rules-based medicine, inc.																																																			-799,000
acquisition of rules-based medicine, inc. (see note 14), net of cash acquired
cash and cash equivalents contributed to myriad pharmaceuticals, inc.
transfer of assets, net of liabilities to myriad pharmaceuticals, inc.
sale of intellectual property
net (decrease) in cash and cash equivalents
excess tax benefit from stock-based compensation																																																							-12,358,000
proceeds from sales and maturities of marketable investment securities																																																							66,151,000																34,311,000	43,513,000	33,539,000	17,100,000	6,318,000	16,526,000	15,869,000		7,396,000
loss on cost-basis investment
proceeds from maturities marketable investment securities
proceeds from sales marketable investment securities
cash and cash equivilants contributed to myriad pharmaceuticals, inc.
proceeds from sales of and maturities of marketable investment securities																																																									98,251,000
(gain) loss on marketable investment securities																																																											-73,000
proceeds from maturities of marketable investment securities																																																											58,057,000	48,110,000	14,752,000	24,363,000	24,624,000	17,694,000	53,237,000	49,396,000	54,093,000	51,474,000	56,175,000
other-than-temporary impairment on marketable investment securities																																																												0	0
decrease (increase) in other assets
net proceeds from public offering of common stock																																																																				-2,000				-1,000	-7,000
net proceeds from warrants
supplemental disclosures of noncash information
fair value adjustment on marketable investment securities credited to stockholders’ equity
transfer of assets, net of liabilities to myriad pharmaceutical, inc.
cash flows used in investing activities:
other than temporary impairment on marketable investment securities																																																															1,986,000
increase in other assets
supplemental disclosures of noncash investing and financing activities:
fair value adjustment on marketable investment securities charged to stockholders’ equity
sales (purchases) of other assets																																																																	0				0
impairment charge on investments in other companies
acceleration of option vesting
changes in operating assets:
related party receivables																																																																												-400,000	-26,000
purchases of other assets																																																																									0
net increase/(decrease) in cash and cash equivalents
net proceeds from issuance of common stock																																																																											1,124,000	442,000	40,000	565,000	14,000
(gain) loss on disposition of assets																																																																												0	10,000
trade receivables																																																																												-1,031,000	396,000
related party payable
gain on disposition/impairment of assets
gain on sale of investment securities
investments in other companies
proceeds from sale of investments in other companies
purchases of investment securities held-to-maturity
maturities of investment securities held-to-maturity
purchases of investment securities available-for-sale
maturities/sales of investment securities available-for-sale

We provide you with 20 years of cash flow statements for Myriad Genetics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Myriad Genetics stock. Explore the full financial landscape of Myriad Genetics stock with our expertly curated income statements.

The information provided in this report about Myriad Genetics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.